Naquotinib mesylate is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as an inhibitor of specific tyrosine kinases, which are enzymes that play a critical role in the signaling pathways that promote cancer cell growth and survival. By blocking these enzymes, it helps to slow down or stop the proliferation of cancer cells, particularly in cases where traditional chemotherapy may not be effective. It is often investigated for its potential in treating non-small cell lung cancer (NSCLC) and other malignancies driven by specific genetic mutations. Clinical trials have explored its efficacy and safety profile, aiming to provide a more personalized treatment approach for patients with advanced or metastatic cancers. Additionally, its role in overcoming resistance to other targeted therapies is an area of ongoing research, making it a promising candidate in the evolving landscape of cancer treatment.